Schizophrenia News and Research

Latest Schizophrenia News and Research

DCC gene involved in adolescent brain development may play a role in mental health vulnerability

As many parents of mentally ill adults will confirm anecdotally, the first symptoms of "something not quite right" with their children begin to appear during the teen years. It is known that during this teenaged phase of brain development, adolescents are particularly vulnerable to psychiatric disorders, including schizophrenia, depression and drug addiction.

17 Dec 2013

Rich club disconnectivity may be ‘core’ schizophrenia feature

The impaired “rich club” connectivity observed in the brains of patients with schizophrenia is also present in their unaffected siblings, report researchers.

17 Dec 2013

Researchers discover direct evidence of genetic overlap between cognitive ability and schizophrenia

Investigators at The Feinstein Institute for Medical Research have discovered for the first time, direct evidence of a genetic overlap between schizophrenia and general cognitive ability. The findings are published online in Molecular Psychiatry.

17 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

A University of Arkansas researcher and her colleagues have found that secondary conditions and diseases that could become deadly significantly affect how long HIV patients stay in the hospital.

17 Dec 2013

Drug abuse appears to foster brain changes that resemble schizophrenia

Teens who were heavy marijuana users -- smoking it daily for about three years -- had abnormal changes in their brain structures related to working memory and performed poorly on memory tasks, reports a new Northwestern Medicine- study.

16 Dec 2013

Psychiatrists increasingly refuse to accept private insurance as payment

Access to mental health care has become a prominent issue in Congress following mass shootings around the country. But a new study in JAMA Psychiatry, led by researchers at Weill Cornell Medical College, suggests that unless those in need of help have deep pockets, they might have a hard time finding a psychiatrist that will provide the needed services.

13 Dec 2013

Adolescent brain remodeling goes awry in schizophrenia

A crucial reorganization process that occurs in the adolescent brain may be disturbed in those who go on to develop schizophrenia, a study suggests.

12 Dec 2013

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.

12 Dec 2013

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Retrophin, Inc. today announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties.

12 Dec 2013

Researchers develop new screening tool to facilitate diagnosis of Autism Spectrum Disorder in adults

Researchers at Karolinska Institutet in Sweden have developed a new screening tool to facilitate the diagnosis of Autism Spectrum Disorder in adults. The test is presented in the scientific journal Molecular Autism and is unique in that researchers have, as part of their evaluation, compared the group diagnosed with Autism Spectrum Disorder with psychiatric patients.

12 Dec 2013

Schizophrenia treatment responses follow distinct trajectories

The positive and negative symptoms of schizophrenia generally change in parallel with each other, shows research, supporting the notion that the different symptom domains of the condition have a shared underlying pathology.

11 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

GW Pharmaceuticals receives U.S. patent for treating glioma

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

11 Dec 2013

Childhood trauma linked to poor social functioning in adult psychosis

Adults with first-episode psychosis who report childhood trauma tend to have poorer social functioning than those without such a history, a prospective study has shown.

10 Dec 2013

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Repetitive transcranial magnetic stimulation uses a non-invasive and relatively painless tool to stimulate the human brain in vivo using very strong, pulsed magnetic fields. It is also used to explore and elucidate neocortical functions and treat neuropsychiatric disorders.

9 Dec 2013

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Advanced paternal age has been associated with greater risk for psychiatric disorders, such as schizophrenia and autism. With an increase in paternal age, there is a greater frequency of certain types of mutations that contribute to these disorders in offspring.

9 Dec 2013

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.

9 Dec 2013

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design platform.

9 Dec 2013

Brain network disruption crosses psychosis diagnostic boundaries

Disruption of cortical information processing occurs in patients with psychosis regardless of whether they have a psychotic or affective diagnosis, research shows.

6 Dec 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

DCC gene involved in adolescent brain development may play a role in mental health vulnerability

Rich club disconnectivity may be ‘core’ schizophrenia feature

Researchers discover direct evidence of genetic overlap between cognitive ability and schizophrenia

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

Drug abuse appears to foster brain changes that resemble schizophrenia

Psychiatrists increasingly refuse to accept private insurance as payment

Adolescent brain remodeling goes awry in schizophrenia

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Researchers develop new screening tool to facilitate diagnosis of Autism Spectrum Disorder in adults

Schizophrenia treatment responses follow distinct trajectories

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

GW Pharmaceuticals receives U.S. patent for treating glioma

Childhood trauma linked to poor social functioning in adult psychosis

RTMS safe and effective for hallucination in schizophrenia spectrum disorders

Research explores epigenetic effects that contribute to psychiatric disorders in offspring

Janssen announces first-of-its-kind pediatric HIV treatment donation program

Heptares starts HTL9936 Phase 1 study for improving cognitive function in Alzheimer's patients

Brain network disruption crosses psychosis diagnostic boundaries

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

Schizophrenia News and Research

Latest Schizophrenia News and Research

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in